HOME | ABOUT | CONTACT US | PARTNERS stock ticker INVESTORS pick a language
 
  Our Platform Technologies:
  Antivirals Radiation Protection Oncology Bio Barcode Assay Camelidae
Blood Products		 Neutraceuticals
 
CBIA.PK

LATEST NEWS
PRESS RELEASE

CB1400, patented by Canopus BioPharma, enters Phase II clinical trials for the prevention of mucositis in patients with cancer of the head and neck. 
Read more>>

LATEST NEWS
PRESS RELEASE

CB1400, patented by Canopus BioPharma, prevents tumor growth and enhances the anti-tumor effects of cisplatin and cetuximab (Erbitux) 
Read more>>

LATEST NEWS
PRESS RELEASE

Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments through License Agreement with Wisconsin Alumni Research Foundation. 
Read more>>














Recent News

May 08 NEWS
--> Rodman & Renshaw Conference
--> Dr Linda Pullen

October 07 NEWS
--> Hepatitus C Antiviral
--> Acumen Conference
--> Novel Antiviral

August 07 NEWS
--> Press Release

JULY 07 NEWS
--> Name Change

JUNE 07 NEWS
--> Stock Purchase







click here to see archived news...

 
 
  HOME | ABOUT | CONTACT US | PARTNERS | INVESTORS